C-reactive Protein Testing Market Size, Share & Trends Analysis Report By Assay Type (ELISA, Immunoturbidimetric Assay), By Detection Range, By Disease Area (Cancer, Lupus), By End-use, By Region, And Segment Forecasts, 2021 - 2028

Report Overview

The global C-reactive protein testing market size was valued at USD 5.5 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 0.3% from 2021 to 2028. Advancements in nanotechnological tools are expected to provide a lucrative perspective in designing portable bioanalytical assays with high specificity and sensitivity, faster response time, and multiplexing capabilities for onsite accurate disease diagnosis and monitoring.

Plasmonic Nanoparticles (PNPs) are among the tools that can be used for biosensing applications owing to their versatile optical properties. A study was published in July 2021, in which researchers from BabeÈ™-Bolyai University, Romania provided an overview on plasmonic nanoparticles-based assays for C-reactive protein (CRP) detection. In addition, the study demonstrated the use of newly designed point-of-care assays for rapid CRP testing. Such advancements are anticipated to accelerate market growth in the near future.

The COVID-19 pandemic has boosted the revenue generation of the market in 2020. According to NCBI, in October 2020, researchers from Mohammed VI University of Health Sciences, Morocco, studied the use of C-reactive protein as an early predictor of SARS-CoV-2 infection severity. The research stated that CRP level is a simple and independent factor useful for the prediction of infection severity, as well as the easy guidance of primary care.

According to IFCC guidance, C-reactive protein is considered as one of the markers that can be used for evaluating the severity of infection prognostics and therapeutic monitoring. In addition, Chinese guidelines state that CRP tests can be used with other clinical parameters for the evaluation and follow-up of SARS-CoV-2 infection. Companies such as Abbott and Aidian offer products that can be used as supportive diagnostic tools in the management of COVID-19 infection.

For instance, Aidian offers easy-to-use QuikRead go CRP tests and a portable QuikRead go instrument for quantitative measurement of C-reactive protein. Similarly, Abbott offers Afinion 2 Analyzer and Afinion CRP test that delivers results in 3 minutes. Thus, increasing demand for CRP testing in research and clinical settings due to the COVID-19 pandemic is anticipated to positively impact market growth.

Assay Type Insights

The immunoturbidimetric assays dominated the market and accounted for the largest revenue share of 48.5% in 2020. The segment is anticipated to further grow during the forecast period. The application of this technique in several, chronic disorders of the cardiac and respiratory systems is expected to aid in the dominance of the segment in the coming years. Developments in the Chemiluminescence Immunoassay (CLIA) technique to provide accurate results are expected to propel growth in the market, by driving the segment.

Technological advancements in immunoturbidimetric assays are expected to fuel market growth in the coming years. Researchers across the world are actively involved in the development of advanced and innovative assays to support rapid and accurate CRP testing. For instance, according to a study published in January 2021, researchers from DM Vasudevan Agappe Diagnostic Limited, India demonstrated the use of latex-enhanced immunoturbidimetric assay for high sensitivity and wide range C-reactive protein detection in human serum.

Agappe Diagnostic Limited has developed a new reagent for this assay. Furthermore, presence of POC devices based on the principle involved in this technique contributes substantially to the estimated share. For instance, QuickRead CRP, developed by Orion Diagnostica Oy, is an immunoturbidimetric-based, ready-to-use kit for quantitative detection of CRP levels in plasma, serum, and whole blood samples.

This system provides results in minutes and is specially developed for primary health settings by the company. Also, various latex-enhanced, high-sensitivity immunoturbidimetric systems are available in the market. Such innovations in the field are expected to influence the growth in coming years.

Detection Range Insights

The hs-CRP segment dominated the CRP testing market and accounted for the largest revenue share of 42.8% in 2020. The segment is anticipated to witness a CAGR of 0.3% from 2021 - 2028. This test provides more accurate results than the standard CRP-based assays and has a detection range lower than the detection range of conventional methods. The detection range for high sensitivity CRP is <10 mg/L to >10.0 mg/L.

According to American Heart Association (AHA) and Centers for Disease Control and Prevention (CDC), hs-CRP acts as an independent marker that facilitates in the estimation of cardiovascular disorders such as myocardial infarction. In addition, a research study on inflammatory markers found the association between high hs-CRP levels and disease activities in rheumatoid arthritis. According to the study, a higher level of serum hs-CRP is a potential biomarker for determining the pathogenesis of rheumatoid arthritis.

In addition, the development of various hs-CRP-based POC testing devices by various market entities is also predicted to boost market growth. Technological advancements in conventional CRP methods are anticipated to propel the segment growth during the forecast period. The introduction of nano-bio hybrid material in CRP biosensors has emerged as a promising approach for rapid and accurate measurement of CRP using portable biosensors.

In a study published in May 2021, researchers from Korea summarized advances in electrochemical, spectroscopy-based, and electrical CRP biosensors composed of biomaterial, and nanomaterial hybrids. Such studies are anticipated to increase the adoption of advanced CRP tools by end users.

Disease Type Insights

The Cardiovascular diseases (CVD) segment dominated the market and accounted for the largest revenue share of 21.8% in 2020. An increase in the prevalence of CVDs is the major factor contributing to the growth of the market. Adoption of a sedentary lifestyle, obesity, hypertension, and diabetes are few risk factors associated with CVDs. C-reactive protein is found to be the most extensively studied noninvasive biomarker for inflammation in CVDs and several hs-CRP assays are currently available in the market.

The cancer segment held the second-largest revenue share in 2020. It is a crucial public health burden across the globe. According to the WHO, there are more than 1.9 million deaths and 3.7 million new cancer cases every year in the European region, hence, there is a need for large-scale adoption of POC CRP testing solutions to aid in the management of cancer in developed and developing countries across the globe.

Furthermore, the rapid transmission of COVID-19 infection has increased the demand for CRP testing services and products. This has led to an increase of more than 600%; from 2019 to 2020; in the revenue generation of other disease-type segments. German researchers have developed a new, innovative therapy option based on CRP.

This study was published in the Journal for Therapeutic Apheresis and Dialysis in June 2020. This therapy option includes C-reactive protein apheresis for SARS-CoV-2 patients suffering from organ damage. This study concludes that this therapeutic option presents an extremely low risk and expected benefit for patients.

End-use Insights

The hospitals segment dominated the market and accounted for the largest revenue share of 27.2% in 2020. The growth of the hospitals segment can be attributed to the rising penetration of CRP testing in hospitals, especially in developing regions across the world. The rising incidence of COVID-19, cardiovascular disorders, and cancer-related infections has led to an increase in hospital visits and thereby the adoption of CRP testing kits. This would further provide growth avenues to the market.

The clinics segment held a substantial market share throughout the analysis period. CRP testing technology has expanded in the past few years with noteworthy developments in areas of point-of-care and hs-CRP. These advancements have increased the feasibility of the use of CRP tests in clinical practice today. Owing to the ongoing COVID-19 pandemic, clinics are expected to witness an increase in demand for CRP testing. This can be attributed to the potential of CRP testing in determining the severity of SARS-CoV-2 infection in infected patients.

Regional Insights

North America dominated the C-reactive protein testing market and accounted for the largest revenue share of 39.5% in 2020. Increasing adoption of innovative, advanced technology and high focus on clinical research in North America are among the factors driving the market. Owing to the high cancer prevalence in the U.S., there is a significant usage of CRP tests.

According to the American Cancer Society, prostate cancer is the second most diagnosed cancer in the U.S. and the third leading cause of death in men. Estimates from the same source also indicated that one in 41 men in the U.S. will die as a result of prostate cancer. According to the Prostate Cancer Foundation, in the U.S., prostate cancer is one of the most common types of non-skin cancers. In addition, the American Cancer Society and American Urological Association both recommend adding the PSA test to the annual digital rectal examination that millions of men undergo in the U.S. This is further anticipated to drive market growth in North America.

The ongoing COVID-19 pandemic is expected to positively impact the market. Various research studies have been conducted to evaluate CRP as a prognostic indicator in COVID-19 patients. For instance, a study was published in November 2020 by researchers from the U.S. The study supported the utility of daily CRP values in hospitalized COVID-19 patients. The CRP levels can also be used as early thresholds. Such studies are anticipated to increase the demand for CRP testing in the region.

Key Companies & Market Share Insights

Key market participants are involved in growth strategies to expand their C-reactive protein testing business. For instance, in July 2021, Boditech Med, Inc. announced plans for expansion of its production capacity two-fold. In March 2021, the company also announced the construction of a new R&D Center in Chuncheon, South Korea with an investment of USD 6 million. This center is expected to be operational by March 2022. Some of the prominent players in the C-reactive protein testing market include:

• Thermo Fisher Scientific, inc.

• F. Hoffmann-La Roche Ltd.

• Danaher

• Quest Diagnostics

• Siemens Healthineers AG

• Abbott

• Merck KGaAA

• Zoetis

• Ortho Clinical Diagnostics

• Getein Biotech, Inc.

• HORIBA, Ltd

• Randox Laboratories Ltd.

• BODITECH MED, INC.

• Aidian

C-reactive Protein Testing Market Report Scope

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2028. For the purpose of this study, Grand View Research has segmented the global C-reactive protein testing market report on the basis of assay type, detection range, disease area, end-use, and region:

• Assay Type Outlook (Revenue, USD Million, 2017 - 2028)

  • Immunoturbidimetric Assay

  • ELISA

    • Clinical

    • Non-clinical

  • Chemiluminescence Immunoassay

  • Others

• Detection Range Outlook (Revenue, USD Million, 2017 - 2028)

  • hs-CRP

  • Conventional CRP

  • cCRP

• Disease Area Outlook (Revenue, USD Million, 2017 - 2028)

  • Cardiovascular Diseases

  • Cancer

  • Rheumatoid Arthritis

  • Inflammatory Bowel Disease

  • Endometriosis

  • Lupus

  • Others

• End-use Outlook (Revenue, USD Million, 2017 - 2028)

  • Clinics

    • By Entity

      • Physician Offices

      • Small Clinics

      • Others

    • By Settings

      • Urban Setting

      • Rural Setting

  • Hospitals

  • Urban Setting

  • Rural Setting

  • Laboratories

    • Urban Setting

    • Rural Setting

  • Assisted Living Healthcare Facilities

    • Urban Setting

    • Rural Setting

  • Home

  • Others

• Regional Outlook (Revenue, USD Million, 2017 - 2028)

  • North America

    • U.S.

    • Canada

  • Europe

    • Germany

    • U.K.

  • Asia Pacific

    • China

    • Japan

  • Latin America

    • Brazil

  • Middle East and Africa (MEA)

    • South Africa